Janssen's sales of Darzalex exceed expectations

Johnson & Johnson’s pharmaceutical arm Janssen has sold more of the Danish-developed cancer drug Darzalex in the first quarter of the year than analysts had anticipated.

Photo: Lars Møller / Genmab / PR

Sales of the Genmab-developed bone marrow cancer drug, Darzalex, which Johnson & Johnson has licensed, surpassed projections for the first quarter of 2022, as revealed by Johnson & Johnson’s financial report on Tuesday.

Darzalex sales came to USD 1.86bn compared to the consensus analyst estimate of USD 1.67bn, according to Bloomberg News.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs